"Hydroxamic Acids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of weak acids with the general formula R-CONHOH.
| Descriptor ID |
D006877
|
| MeSH Number(s) |
D02.092.570.394 D02.241.511.372
|
| Concept/Terms |
Hydroxamic Acids- Hydroxamic Acids
- Acids, Hydroxamic
- Hydroxamic Acid
- Acid, Hydroxamic
|
Below are MeSH descriptors whose meaning is more general than "Hydroxamic Acids".
Below are MeSH descriptors whose meaning is more specific than "Hydroxamic Acids".
This graph shows the total number of publications written about "Hydroxamic Acids" by people in this website by year, and whether "Hydroxamic Acids" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 2 | 3 |
| 2010 | 1 | 3 | 4 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 2 | 4 |
| 2014 | 2 | 2 | 4 |
| 2015 | 5 | 1 | 6 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydroxamic Acids" by people in Profiles.
-
Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer. Mol Carcinog. 2020 08; 59(8):955-966.
-
Targeting Mobilization of Ferrous Iron in Pseudomonas aeruginosa Infection with an Iron(II)-Caged LpxC Inhibitor. ACS Infect Dis. 2019 08 09; 5(8):1366-1375.
-
Disruption of lipid-raft localized Gas/tubulin complexes by antidepressants: a unique feature of HDAC6 inhibitors, SSRI and tricyclic compounds. Neuropsychopharmacology. 2018 06; 43(7):1481-1491.
-
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20; 35(24):2745-2753.
-
Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice. Nat Commun. 2015 Sep 23; 6:8250.
-
Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. J Natl Cancer Inst. 2015 Nov; 107(11).
-
In Vitro Radiosensitization of Esophageal Cancer Cells with the Aminopeptidase Inhibitor CHR-2797. Radiat Res. 2015 Sep; 184(3):259-65.
-
Transcriptome Analysis of Pig In Vivo, In Vitro-Fertilized, and Nuclear Transfer Blastocyst-Stage Embryos Treated with Histone Deacetylase Inhibitors Postfusion and Activation Reveals Changes in the Lysosomal Pathway. Cell Reprogram. 2015 Aug; 17(4):243-58.
-
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015 Apr; 16(4):447-56.
-
A lesson from vorinostat in pleural mesothelioma. Lancet Oncol. 2015 Apr; 16(4):359-60.